|Bid||67.00 x 1000|
|Ask||68.73 x 800|
|Day's Range||67.54 - 70.41|
|52 Week Range||42.80 - 71.21|
|Beta (3Y Monthly)||1.01|
|PE Ratio (TTM)||149.70|
|Earnings Date||Jul 31, 2019 - Aug 5, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||72.29|
Repligen stock is the IBD Stock Of The Day after the medical technology company "shot the lights out" during the first quarter, and posted its best organic revenue growth in three years.
Zacks.com featured highlights include: Strategic Education, Repligen, Kinsale Capital, Arcosa and OSI Systems
Mallinckrodt (MNK) concludes enrollment in the phase III study on terlipressin, currently under development for treating adult patients with Hepatorenal Syndrome Type 1.
Repligen (RGEN) delivered earnings and revenue surprises of 7.69% and 0.21%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Waltham, Massachusetts-based company said it had net income of 17 cents per share. Earnings, adjusted for one-time gains and costs, came to 28 cents per share. The drug developer posted revenue of ...
Reports first quarter revenue of $60.6 million, representing 35% year-over-year growth and 37% organic growthRaises revenue guidance to $235-$241 million for full year 2019,.
NEW YORK, NY / ACCESSWIRE / May 9, 2019 / Repligen Corp. (NASDAQ: RGEN ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 9, 2019 at 8:30 AM Eastern Time. ...
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and...
During Evoke Pharma's (EVOK) Q1 conference call, investor focus will be on its progress and issues related to the NDA submission for Gimoti to treat diabetic gastroparesis.
Repligen Corp NASDAQ/NGS:RGENView full report here! Summary * Bearish sentiment is moderate and increasing * Economic output in this company's sector is expanding Bearish sentimentShort interest | NegativeShort interest is moderately high for RGEN with between 10 and 15% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on April 29. Money flowETF/Index ownership | NeutralETF activity is neutral. The net inflows of $3.67 billion over the last one-month into ETFs that hold RGEN are not among the highest of the last year and have been slowing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Solid product performance and excellent market position, driven by innovation, quality products, strong brand and retail partnerships, are likely to drive Turtle Beach's (HEAR) first-quarter results.
WALTHAM, Mass., May 02, 2019 -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2019 financial results on Thursday, May 9,.
Repligen Corporation (RGEN) today announced the pricing of an underwritten public offering of 2,734,375 shares of its common stock at a public offering price of $64.00 per share. In addition, Repligen Corporation has granted the underwriters a 30-day option to purchase up to an additional 410,156 shares of its common stock at the public offering price, less underwriting discounts and commissions. Repligen expects proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, to be approximately $175 million, excluding any exercise of the underwriters’ option to purchase additional shares.
Repligen Corporation (RGEN) today announced that it has commenced an underwritten public offering of $175,000,000 in shares of its common stock. In addition, Repligen Corporation expects to grant the underwriters a 30-day option to purchase up to an additional $26,250,000 in shares of its common stock in connection with the proposed public offering. All shares of common stock will be offered by Repligen Corporation.
Does Repligen Corporation (NASDAQ:RGEN) represent a good buying opportunity at the moment? Let’s briefly check the hedge fund interest towards the company. Hedge fund firms constantly search out bright intellectuals and highly-experienced employees and throw away millions of dollars on satellite photos and other research activities, so it is no wonder why they tend to […]
Repligen Corporation (RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into a definitive agreement to acquire privately-held C Technologies, Inc. for approximately $240 million, comprised of $192 million in cash plus $48 million in Repligen common stock.
Repligen raised CEO Tony Hunt's pay from $3,044,785 in 2017 to $13,893,326 last year — an increase of 356 percent.
If you own shares in Repligen Corporation (NASDAQ:RGEN) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure of volatility. Volatility is considered to be a m...